Malignant Progression Contributes to the Failure of Combination Therapy for Atypical Meningiomas

Qing Zhang; Zheng Wen; Zheng Wen; Zheng Wen; Zheng Wen; Ming Ni; Ming Ni; Ming Ni; Ming Ni; Da Li; Da Li; Da Li; Da Li; Ke Wang; Ke Wang; Ke Wang; Ke Wang; Gui-Jun Jia; Gui-Jun Jia; Gui-Jun Jia; Gui-Jun Jia; Zhen Wu; Zhen Wu; Zhen Wu; Zhen Wu; Li-Wei Zhang; Li-Wei Zhang; Li-Wei Zhang; Li-Wei Zhang; Wang Jia; Wang Jia; Wang Jia; Wang Jia; Liang Wang; Liang Wang; Liang Wang; Liang Wang; Jun-Ting Zhang; Jun-Ting Zhang; Jun-Ting Zhang; Jun-Ting Zhang

doi:10.3389/fonc.2020.608175

Frontiers in Oncology (Jan 2021)

Malignant Progression Contributes to the Failure of Combination Therapy for Atypical Meningiomas

Qing Zhang,
Zheng Wen,
Zheng Wen,
Zheng Wen,
Zheng Wen,
Ming Ni,
Ming Ni,
Ming Ni,
Ming Ni,
Da Li,
Da Li,
Da Li,
Da Li,
Ke Wang,
Ke Wang,
Ke Wang,
Ke Wang,
Gui-Jun Jia,
Gui-Jun Jia,
Gui-Jun Jia,
Gui-Jun Jia,
Zhen Wu,
Zhen Wu,
Zhen Wu,
Zhen Wu,
Li-Wei Zhang,
Li-Wei Zhang,
Li-Wei Zhang,
Li-Wei Zhang,
Wang Jia,
Wang Jia,
Wang Jia,
Wang Jia,
Liang Wang,
Liang Wang,
Liang Wang,
Liang Wang,
Jun-Ting Zhang,
Jun-Ting Zhang,
Jun-Ting Zhang,
Jun-Ting Zhang

Affiliations

Qing Zhang: Department of Neurosurgery, Chinese People’s Liberation Army General Hospital, Beijing, China
Zheng Wen: Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
Zheng Wen: China National Clinical Research Center for Neurological Diseases, Beijing, China
Zheng Wen: Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China
Zheng Wen: Beijing Key Laboratory of Brain Tumor, Beijing, China
Ming Ni: Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
Ming Ni: China National Clinical Research Center for Neurological Diseases, Beijing, China
Ming Ni: Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China
Ming Ni: Beijing Key Laboratory of Brain Tumor, Beijing, China
Da Li: Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
Da Li: China National Clinical Research Center for Neurological Diseases, Beijing, China
Da Li: Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China
Da Li: Beijing Key Laboratory of Brain Tumor, Beijing, China
Ke Wang: Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
Ke Wang: China National Clinical Research Center for Neurological Diseases, Beijing, China
Ke Wang: Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China
Ke Wang: Beijing Key Laboratory of Brain Tumor, Beijing, China
Gui-Jun Jia: Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
Gui-Jun Jia: China National Clinical Research Center for Neurological Diseases, Beijing, China
Gui-Jun Jia: Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China
Gui-Jun Jia: Beijing Key Laboratory of Brain Tumor, Beijing, China
Zhen Wu: Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
Zhen Wu: China National Clinical Research Center for Neurological Diseases, Beijing, China
Zhen Wu: Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China
Zhen Wu: Beijing Key Laboratory of Brain Tumor, Beijing, China
Li-Wei Zhang: Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
Li-Wei Zhang: China National Clinical Research Center for Neurological Diseases, Beijing, China
Li-Wei Zhang: Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China
Li-Wei Zhang: Beijing Key Laboratory of Brain Tumor, Beijing, China
Wang Jia: Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
Wang Jia: China National Clinical Research Center for Neurological Diseases, Beijing, China
Wang Jia: Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China
Wang Jia: Beijing Key Laboratory of Brain Tumor, Beijing, China
Liang Wang: Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
Liang Wang: China National Clinical Research Center for Neurological Diseases, Beijing, China
Liang Wang: Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China
Liang Wang: Beijing Key Laboratory of Brain Tumor, Beijing, China
Jun-Ting Zhang: Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
Jun-Ting Zhang: China National Clinical Research Center for Neurological Diseases, Beijing, China
Jun-Ting Zhang: Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China
Jun-Ting Zhang: Beijing Key Laboratory of Brain Tumor, Beijing, China

DOI: https://doi.org/10.3389/fonc.2020.608175
Journal volume & issue: Vol. 10

Abstract

Read online

ObjectiveTo investigate the independent risk factors for recurrence in intracranial atypical meningiomas (AMs) treated with gross total resection (GTR) and early external beam radiotherapy (EBRT).MethodsClinical, radiological, and pathological data of intracranial AMs treated with GTR-plus-early-EBRT between January 2008 and July 2016 were reviewed. Immunohistochemical staining for Ki-67 was performed. Kaplan–Meier curves and univariate and multivariate Cox proportional hazards regression analyses were used to explore independent predictors of tumor recurrence. Chi square test was performed to compare variables between subgroups.ResultsForty-six patients with intracranial AMs underwent GTR and early EBRT. Ten (21.7%) recurred and three (6.5%) died during a median follow-up of 76.00 months. Univariate and multivariate Cox analyses revealed that malignant progression (MP) (P = 0.009) was the only independent predictor for recurrence, while Ki-67 was of minor value in this aspect (P = 0.362). MP-AMs had a significantly higher recurrence rate (P = 0.008), a higher proportion of irregularly shaped tumors (P = 0.013) and significantly lower preoperative Karnofsky Performance Scale (KPS) scores (P = 0.040) than primary (Pri) AMs. No significant difference in Ki-67 expression was detected between these subgroups (P = 0.713).ConclusionsMP was significantly correlated with an increased incidence of recurrence in GTR-plus-early-EBRT-treated intracranial AMs. Significantly higher frequencies of tumor relapse and irregularly shaped tumors and lower preoperative KPS scores were observed in MP-AMs compared with Pri-AMs. Ki-67 expression is of minor value in predicting tumor recurrence or distinguishing tumor origins in AMs.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords